Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides

Br J Dermatol. 2020 Jun;182(6):1503-1504. doi: 10.1111/bjd.18806. Epub 2020 Feb 12.

Authors

R André¹, C Ram-Wolff¹, M Battistella², R Peffault de Latour³, A Petit¹, J D Bouaziz¹, P Brice³, M Bagot¹, A de Masson¹

Affiliations

¹ Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France.
² Departments of Pathology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France.
³ Departments of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France.

PMID: 31854457
DOI: 10.1111/bjd.18806

No abstract available

Publication types

Letter

MeSH terms

Brentuximab Vedotin
Hematopoietic Stem Cell Transplantation*
Humans
Immunoconjugates*
Mycosis Fungoides* / drug therapy
Skin Neoplasms* / drug therapy
Treatment Outcome

Substances

Immunoconjugates
Brentuximab Vedotin